Darren Patti - Telix Pharmaceuticals Group Officer
| TLX Stock | 31.14 0.81 2.67% |
Executive
Darren Patti is Group Officer of Telix Pharmaceuticals
| Age | 53 |
| Address | 55 Flemington Road, North Melbourne, VIC, Australia, 3051 |
| Phone | 61 3 9093 3855 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0533 % which means that it generated a profit of $0.0533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1392 %, meaning that it generated $0.1392 on every $100 dollars invested by stockholders. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to gain to about 190.1 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 480.9 M in 2025Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Kurinksy | Qbe Insurance Group | N/A | |
| Peter Nelson | G8 Education | N/A | |
| Rebecca Niemiec | Janison Education Group | N/A | |
| AGIA AGIA | Qbe Insurance Group | N/A | |
| BAcc GradDipAFISIA | Charter Hall Education | N/A | |
| Maria Clemente | Janison Education Group | N/A | |
| Kim Cootes | Air New Zealand | N/A | |
| Nikki Dines | Air New Zealand | N/A | |
| Miriam Patterson | Charter Hall Education | N/A | |
| Carola Fratini | Qbe Insurance Group | N/A | |
| Sharyn Williams | G8 Education | N/A | |
| Charles Cygal | Qbe Insurance Group | N/A | |
| LLB BCom | Air New Zealand | N/A | |
| Ed Young | Janison Education Group | N/A | |
| Gregory Foran | Air New Zealand | 64 | |
| BEc BA | Collins Foods | 62 | |
| Peter Burton | Qbe Insurance Group | N/A | |
| Andrew Broughton | Qbe Insurance Group | N/A | |
| BSc FCPA | Qbe Insurance Group | N/A | |
| Andrew Leyden | Collins Foods | N/A | |
| Mathew Bolland | Air New Zealand | N/A | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0533 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MBA, Chief Medicine | ||
| Meredith Crowe, Interim Culture | ||
| BSc BSc, Chief Scientist | ||
| Christian Davis, EMEA Marketing | ||
| Darren PharmD, Group Officer | ||
| Kyahn Williamson, Sr Relations | ||
| MBA MD, Group Officer | ||
| Dov Gardin, Sustainability Risk | ||
| Shintaro BSc, President Japan | ||
| BEng DPhil, Group CoFounder | ||
| Kyahn BA, Senior Relations | ||
| Richard MBA, Chief Therapeutics | ||
| Lena LLB, General Counsel | ||
| Darren Patti, Group Officer | ||
| Craig Ulrick, Chief Officer | ||
| MBA LLB, Chief International | ||
| Lena MoranAdams, G Counsel | ||
| Michelle Hickey, Senior Operations | ||
| LLB BSc, Group Secretary | ||
| Thomas Fromm, Vice Sales | ||
| Ted Stephens, Vice Marketing | ||
| Andreas MD, Chief Director | ||
| Amanda Griffin, Communications Mang | ||
| Meredith BDES, Senior Culture | ||
| BBus FCPA, Group Officer | ||
| AGIA ACG, Risk Governance | ||
| Mary Jessel, Senior Affairs |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0533 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 10.42 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Insiders | 41.16 % | ||||
| Shares Owned By Institutions | 17.14 % | ||||
| Price To Book | 20.67 X | ||||
| Price To Sales | 13.38 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.